

Unlocking New Therapies and Diagnostics for a Healthier Tomorrow?

Experts will share recent developments, challenges and trends in the field of Theranostics

SENN

- Novel Therapies for Treatments of Cancer and Inflammatory Diseases
- Opportunities and Challenges in the Design of Diagnostics and Radionuclide Therapy
- Targets for Radiopharmaceuticals beyond Oncology

REGISTER NOW!

Exclusive Online Webinar followed by Panel Discussion
October 31st 2024, 17:00 – 18:30 CET

Program

- 17:00 – 17:05** Introduction of Speakers (Senn Chemicals)
- 17:05 – 17:20** Radiopharmaceuticals beyond Oncology - Targeting CXCR4 to expand the clinical utility of PET/CT (Pentixapharm)
- 17:20 – 17:35** Optimisation of FAP ligands for the delivery of therapeutic radionuclides – from bench to bedside (Philochem)
- 17:35 – 17:50** The Role of Gastrin Releasing Peptide Receptor in PET Diagnostics and Radionuclide Therapy (Inselspital Bern)
- 17:50 – 18:30** Panel Discussion including Q & A with Prof. Dr. med Schaefer

Speakers

Dr. Dirk Pleimes
Chief Medical Officer
Pentixapharm

Dr. Jacqueline Mock
Clinical Project Manager
Philochem

PD. Dr. Eleni Gourni
Head of Radiopharmacy Lab
Nuclear Medicine Department
Inselspital Bern

Prof. Dr. med. Niklaus Schaefer
Professor of Nuclear Medicine
Univ. Lausanne / CHUV



Dr. Dirk Pleimes is an entrepreneurial, medical professional with over 18 years of experience in drug development, particularly in the fields of immunology, oncology and medical countermeasures. He holds an M.D. from the Charité – Humboldt University of Berlin, where he also completed a diploma in Tropical Medicine and Public Health. Dr. Pleimes held global drug development leadership roles in both large pharmaceutical companies, such as Schering and Bayer as well as Chief Science and Medical Officer positions in the entrepreneurial sphere, where he has successfully co-founded and led three pharmaceutical start-ups. His work has been pivotal in advancing therapeutic small molecules and biologics from early discovery stages to clinical trials. In his current role as Chief Medical Officer at Pentixapharm AG, Dr. Pleimes is responsible for overseeing research and development initiatives and teams developing early-stage antibody technologies and advanced clinical stage radiodiagnostics & radiotherapies.



Dr. Jacqueline Mock studied Interdisciplinary Sciences with a focus on biology and chemistry at ETH Zurich. Following her MSc degree, she joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences at ETH Zurich where she obtained her PhD for the thesis entitled “TNF superfamily members as payloads for antibody-cytokine anticancer therapeutics”. She is passionate about the development of targeted delivery approaches for various therapeutic payloads such as immunomodulatory cytokines, radionuclides and cytotoxic drugs with the aim of selectively increasing the concentration of the bioactive payload at the site of disease. She currently works as Clinical Project Manager for the Philogen group, where she works with a multidisciplinary team on the clinical translation of novel therapeutic candidates such as targeted radiopharmaceuticals and antibody-cytokine conjugates. Recent projects in which she is involved include a diagnostic phase I clinical trial of a novel imaging agent called 68Ga-OncoFAP and a phase I therapy trial with a new radioligand therapeutic called 177Lu-OncoFAP-23.



PD Dr. Eleni Gourni is the Head of the Radiopharmacy Lab of the Nuclear Medicine Department at the University Hospital of Bern, Switzerland. She received her Ph.D. in Radiopharmacy from the University of Athens, Greece. She completed a Habilitation (Venia Legendi) in Radiopharmaceutical Science at the University of Bern. Dr. Gourni has held various prestigious positions, including Senior Scientific Associate at the Cancer Research UK Cambridge Institute and Researcher at the University of Oslo, where she held a Marie Curie Fellowship. Her extensive postdoctoral work spanned several institutions, including the University Hospital Freiburg and the Technical University of Munich in Germany. Her expertise includes the preclinical evaluation of radiopharmaceuticals, PET/SPECT imaging, and targeted radionuclide therapy, with a particular focus on peptides, antibodies, small-molecules and cancer tumor models. Her research has been published extensively, and she is the recipient of numerous awards, including multiple Alavi-Mandel awards and recognition for outstanding scientific manuscripts in the Journal of Nuclear Medicine. She is an active member of key scientific societies, such as the European Association of Nuclear Medicine and the Society of Radiopharmaceutical Sciences. Dr. Gourni's work in radiopharmaceuticals continues to contribute to advancements in molecular imaging and targeted therapies for cancer.



Professor Dr. med. Niklaus Schaefer is a globally recognized expert in nuclear medicine and theranostics. He is a Full Professor at the University of Lausanne and Chief Physician at the Centre Hospitalier Universitaire Vaudois (CHUV). Prof. Schaefer holds certifications in internal medicine, medical oncology, and nuclear medicine. After earning his medical degree and doctorate at the University of Zurich, he pursued a combined academic and clinical career at the University Hospital of Zurich and Johns Hopkins University. He advanced to Assistant Professor at Zurich and earned a Venia Legendi in Oncology and Nuclear Medicine. In 2015 he was appointed Associate Professor of Nuclear Medicine at the University of Lausanne and Associate Physician at CHUV. He founded a theranostic center becoming one of the largest in Switzerland, offering a full range of advanced treatments and imaging. The center currently performs up to 500 therapies annually. Prof. Schaefer also established and leads the Centre of Excellence (ENETS) for Neuroendocrine Tumors in Lausanne. Prof. Schaefer has shared his research through numerous national and international conferences and has published extensively in leading scientific journals. His work has been recognized with several awards, including honors at the annual congress of the Society of Nuclear Medicine (SNMMI) and the Marie Curie Award from the European Association of Nuclear Medicine (EANM). Prof. Schaefer is a member of various national and international committees.